You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Long-Term Use of Mood Stabilizers and Its Impact on the Quality of Life of Chinese Patients With Schizophrenia

Xiang, Yu-Tao MD, PhD*†; Weng, Yong-Zhen MD*; Leung, Chi-Ming MD†; Tang, Wai-Kwong MD†; Ungvari, Gabor S. MD, PhD†

Clinical Neuropharmacology:
doi: 10.1097/WNF.0b013e31815d25b5
Original Articles
Abstract

Objectives: To date, no studies have investigated the prescription patterns of mood stabilizers (MSs) in Chinese patients with schizophrenia. This study examined the frequency and sociodemographic and clinical correlates of MS prescription for outpatients with schizophrenia in Hong Kong (HK) and Beijing (BJ), China.

Methods: Five hundred five clinically stable outpatients with schizophrenia were randomly selected and interviewed in HK and BJ using standardized assessment instruments. Basic sociodemographic and clinical data and psychotropic drug prescriptions were collected at the time of a diagnostic interview.

Results: Thirty-four (6.7%) of the patients were prescribed MSs in the whole sample, with 10.2% and 3.2% of the HK and BJ samples, respectively. Use of MSs was associated with a history of violence, number of admissions, and severity of extrapyramidal side effects. In multiple logistic regression analysis, number of admissions, study site, sex, and length of illness were significantly associated with MSs.

Conclusions: Although the ethnic and clinical characteristics of the 2 samples were nearly identical, there was a wide variation in the frequency of MS prescriptions between HK and BJ.

Author Information

*Beijing An Ding Hospital, Capital Medical University, Beijing; and †Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China.

Address correspondence and reprint requests to Yu-Tao Xiang, MD, PhD, Department of Psychiatry, Shatin Hospital, Shatin, N.T., Hong Kong SAR, China; E-mail: xyutly@cuhk.edu.hk

© 2009 Lippincott Williams & Wilkins, Inc.